Still Needled By Icahn, Forest Nominates Three To Board
This article was originally published in The Pink Sheet Daily
The specialty pharma countered the activist investor's June challenge with its own nominees, while defending its diversification strategy.
You may also be interested in...
One exception to the slow-growth outlook is the surprise success of Bystolic (nebivolol), the 16th beta blocker to enter the heavily generalized market, but a product the firm has been able to differentiate more by its tolerability than its efficacy.
Activist investor Carl Icahn is at it again, announcing plans May 30 to propose a minority slate of new board members for patent-cliff-challenged specialty pharma Forest Laboratories.
Forest shareholders elect the company's slate of board members at its annual meeting, shooting down activist investor Carl Icahn's picks.